News Briefs Archive

AI-Based Platform for Clinical Decision Workflows Launches

3d rendering of human on geometric element technology background represent artificial intelligence and cyber space conceptAdvanced technology to enhance your clinic operations 

Feb. 28, 2024

RetinAI US, Inc., via its parent company Ikerian AG, announced the launch of the artificial intelligence (AI)-based RetinAI Discovery for Clinics software platform with two product versions for both ophthalmic (MD) and optometric (OD) clinics.A subsidiary of Ikerian (formerly known as RetinAI Medical AG), RetinAI is a Swiss and U.S.-based software company developing software solutions to accelerate clinic, research and pharmaceutical workflows across the globe through advanced machine learning and computer vision.

Medical & Imaging Data Management System

The RetinAI Discovery platform is a medical and imaging data management system designed to analyze ophthalmic images such as optical coherence tomography (OCT) scans and color fundus photography (CFP) from a variety of medical devices.

FDA 510(k)-cleared in 2022. The integrated platform delivers cloud- and web-based access to enable a collaborative and interactive, real-time analysis of clinical cases.

How the Technology Helps Clinical Operations

Per RetinAI, Discovery for Clinics (plus the AI models) have been designed to accelerate and advance the following clinical areas:

Clinical decision workflows
Teleophthalmology management
Referral decisions
Patient management

The multi-modality platform is intended to combine, aggregate and connect large datasets on a singular cloud-based repository for data, which is then automatically analyzed using RetinAI’s research-use-only (RUO) AI algorithms.

This analysis is examined for accelerated and AI-biomarker-based treatment decisions.

Note: the AI models are capable of being processed on DICOM and other OCT and fundus imaging formats: PDF, JPEG, PNG, and TIFF files.

Specifics on these AI Models

Available in both versions are the following models:

Fluid segmentation
Intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED)
Layer segmentation
Retinal nerve fiber layer (RNFL), ganglion cell layer, inner plexiform layer (IPL) and retinal pigment epithelium (RPE) (see here for the complete list of layers)
Advanced layer segmentation
Quantification of the retinal layers with photoreceptors, the RPE and fluids
Segments/quantifies hyperreflective foci (HRF) and amorphous material
Macula biomarkers
Probability of presence/absence of retinal biomarkers at a B-scan level in volumes
Any notable differences between the AI models?

The optometry workflow package contains all the AI models mentioned with the exception of geographic atrophy AI Model, which is only available in the ophthalmology version featuring RetinAI’s RUO AI algorithms for a more in-depth viewing and analysis of geographic atrophy (GA), including future atrophy progression via a prediction progression model.

What other similarities are there between the two?

Both versions feature progression analytics for tracking outcome trends and presenting high-quality visualization of disease progression for patients.

They also include:

Connection between healthcare stakeholders and patients through Discovery Passport, which enables physicians to share secure data and create remote questionnaires for patients.
Support for referral networks and clinical trial participation via real-world data collection

Click HERE for details on the ophthalmology version, and HERE for more info on the optometry version and to request a demo (scroll to bottom).

To Top
Subscribe Today for Free...
And join more than 35,000 optometric colleagues who have made Review of Optometric Business their daily business advisor.